Premium
32
Postoperative tumour antigen presentation in murine models of malignancy
Author(s) -
BROWN M.D.,
VIVIAN J.B.,
CURRIE A.J.,
ROBINSON B.W.S.
Publication year - 2006
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2006.06085_32.x
Subject(s) - medicine , malignancy , immune system , cd8 , lymph , antigen , adjuvant , adoptive cell transfer , immunotherapy , pathology , t cell , oncology , immunology
As biological therapies emerge for urological malignancy, determining the impact of surgery on immune function is increasingly important. By uncovering the effects of surgery on tumour antigen, we have enabled a logical approach to immune therapy type, timing, and mode of delivery. Syngeneic AB1‐HA mesothelial tumour was grown subcutaneously in 100 female BALB/c mice aged 6–8 weeks. Once the tumour was 4 × 4 mm in size, complete resection was undertaken. Beginning from the day of surgery and extending to 4 weeks postoperatively, animals were subject to the adoptive transfer of carboxyfluoroscein diacetate succinimidyl ester (CFSE) stained tumour‐specific CD8 cells, followed by fluorescence activated cell sorting (FACS) analysis. Antigen presentation occurred only in the draining lymph nodes ( P < 0.005), and was absent by the second postoperative week ( P = 0.35). Our results suggest local adjuvant therapy may be effective in the early postoperative phase, and tumour vaccines in the longer term.